Pfizer Corporation

University of California

Dyax Corporation

Leland Stanford Junior University

Xoma Technology Ltd.

The Cbr Institute for Biomedical Research, Inc.

Cornell University

Beth Israel Deaconess Medical Center, Inc.

Isaac J Rondon

Lauren K Ely

Robert Charles Ladner

Kenan Christopher Garcia

Paul Henry Bessette

Jeffrey A Bluestone

Natasha K Crellin

Eleonora Trotta

Timothy Alan Springer

Dean Sheppard

Marina Roell

Daniel H Bedinger

Edward Hirsch Cohen

Motomu Shimaoka

Amha Atakilit

Joseph Dal Porto

Dominique Meyer

Matthew Ross Drever

Charles Ray Holst

Dharmaraj Samuel

Kyle Steven Niessen

Lioudmila Tchistiakova

Shaun R Coughlin

Kimberly Ann Marquette

Lewis C Cantley

Lidia Mosyak

Eric M Bennett

Chao Bai Huang

Yun Cheol Kim

Irina Apostolou

Rosemary J Akhurst

Tovo David

Brooke M Emerling

Huilan Gao

Thomas Mikita

Rosemary J Akurst

Stephen P Soltoff

Cindy M Hodakoski

Brian Gaither Bates

Edward Christian Rosfjord

Georgios Poulogiannis

Hui Liu

The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

CDCP1 antibodies and antibody drug conjugates

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin. The invention includes uses, and associated methods of using the antibodies.

Method of treating cancer using anti-AV8 antibodies

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R&#x3b1; and IL-2R&#x3b2;. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

Anti-IL-2 antibodies and compositions and uses thereof

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to &#x3b1;v&#x3b2;8 integrin. The invention includes uses, and associated methods of using the antibodies.

Anti-AVB8 antibodies and compositions and uses thereof

In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

Antibodies to coagulation factor XIa and uses thereof

The present disclosure relates to novel triple tag sequences that may comprise a 6&#xd7; histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides.

Triple tag sequence and methods of use thereof

Triple tag sequences and methods of use thereof

The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 ('aLFA-1 '), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

Conformation specific antibodies

The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 ('aLFA-1'), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding CEA, which is overexpressed in adenocarcinomas of endodermally derived digestive system epithelia and fetal colon. Such polypeptides and disclosed derivatives are useful, e.g., as imaging agents for CEA-expressing tumors.

Binding peptides for carcinoembryonic antigen (CEA)

Growing community of inventors

San Francisco, CA, United States of America

Isaac J Rondon